To investigate the long-term effects of efavirenz on cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL-C) and triglycerides (TG).Methods
Thirty-four HIV-infected patients who commenced efavirenz therapy were monitored for 36 months.Results
In patients with baseline HDL-C < 40 mg · dL−1 an increase in HDL-C from 31 ± 1 mg · dL−1 to 44 ± 2 mg · dL−1 (95% confidence interval 5.9, 21.9, P < 0.01) was observed and remained throughout the follow-up period. Median efavirenz plasma concentration was 1.98 mg · L−1 and a direct correlation between percentage of HDL-C variation or TC/HDL-C ratio and efavirenz plasma concentrations was found.Conclusions
There is evidence of a long-term and concentration-dependent beneficial effect of efavirenz on HDL-C in HIV-infected patients.